美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Aduro Biotech, Inc.

14.60

0.0000

成交量：- -

成交額：- -

市值：2.37億

市盈率：-3.64

高：14.60

開：14.60

低：14.60

收：14.60

52周最高：20.20

52周最低：4.51

股本：1,621.18萬

流通股本：931.67萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-4.0052

每股收益(LYR):-5.1411

淨資產收益率：-87.44%

總資產收益率：-13.90%

市淨率：5.08

市盈率(LYR):-2.84

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Aduro Biotech, Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.aduro.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Aduro Biotech, Inc.最初是於2000年以Oncologic公司的名字在加利福尼亞州註冊成立。在2008年，該公司兼并了海衛生物系統公司，隨後於2009年更名為Aduro生物科技有限公司。2011年6月，該公司重新合併作為特拉華州的公司。該公司是臨床階段的免疫腫瘤公司專註於設計，以刺激對抗癌症堅固耐用的免疫反應第一的一流技術平台的發展，其先導候選產品是一項隨機對照2b期臨床試驗在轉移性胰腺癌。免疫腫瘤包括一種類療法，利用患者的免疫系統，以減慢的生長和擴散，或消除，腫瘤細胞。該公司目前的重點是開發和使用它的LADD和CDN技術平台的商業化最好的一流的癌症療法。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ADRO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADRO\",,,,,undefined,":{"symbol":"ADRO","market":"US","secType":"STK","nameCN":"Aduro Biotech, Inc.","latestPrice":14.595,"timestamp":1601928000000,"preClose":14.595,"halted":8,"volume":0,"delay":0,"floatShares":9316711,"shares":16211801,"eps":-4.005182,"marketStatus":"未開盤","change":0,"latestTime":"10-05 16:00:00 EDT","open":14.595,"high":14.595,"low":14.595,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.005182,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1757318400000},"marketStatusCode":0,"symbolChange":{"newSymbol":"KDNY","executeDate":"2020-10-06"},"adr":0,"adrRate":0,"listingDate":1429070400000,"exchange":"NASDAQ","adjPreClose":14.595,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADRO\",,,,,undefined,":{"symbol":"ADRO","floatShares":9316711,"roa":"-13.90%","roe":"-87.44%","lyrEps":-5.141135,"shares":16211801,"dividePrice":0,"high":14.595,"amplitude":0,"preClose":14.595,"low":14.595,"week52Low":4.5055,"pbRate":"5.08","week52High":20.2,"institutionHeld":0,"latestPrice":14.595,"eps":-4.005182,"divideRate":0,"volume":0,"delay":0,"ttmEps":-4.005182,"open":14.595},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADRO\",params:#limit:5,,,undefined,":[{"date":"2020-11-05","symbol":"ADRO","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2020/09","expectedEps":-0.9,"defaultRemindTime":1604566800000,"name":null,"time":"","dateTimestamp":1604552400000,"actualEps":null},{"market":"US","date":"2020-10-06","symbol":"ADRO","oldSymbol":"ADRO","defaultRemindTime":1601991000000,"newSymbol":"KDNY","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1601956800000},{"market":"US","date":"2020-10-02","symbol":"ADRO","defaultRemindTime":1601645400000,"type":"split","dateTimestamp":1601611200000,"forFactor":5,"toFactor":1,"ratio":5},{"market":"US","date":"2020-08-03","symbol":"ADRO","fiscalQuarterEnding":"2020/06","expectedEps":-0.19,"name":null,"time":"","type":"earning","dateTimestamp":1596427200000,"reportTimeType":"","actualEps":-0.21},{"market":"US","date":"2020-03-09","symbol":"ADRO","fiscalQuarterEnding":"2019/12","expectedEps":-0.21,"name":null,"time":"盤後","type":"earning","dateTimestamp":1583726400000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADRO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADRO","date":"2020-10-05","current":-3.518245,"percent":0.100629,"low":-17.955354,"twenty":-3.193584,"median":-2.392077,"eighty":-0.998298,"high":-0.776981,"avg":-2.170306,"sd":1.390992,"marketCap":227127332},"quantilePoints":[{"date":"2020-09-11","current":-2.969539,"twenty":-3.181028,"median":-2.136189,"eighty":-0.996997,"marketCap":191704546},{"date":"2020-09-18","current":-3.126492,"twenty":-3.181028,"median":-2.279336,"eighty":-0.998298,"marketCap":201836922},{"date":"2020-09-25","current":-2.862812,"twenty":-3.181028,"median":-2.360384,"eighty":-0.998298,"marketCap":184814531},{"date":"2020-10-02","current":-17.955354,"twenty":-3.181028,"median":-2.384691,"eighty":-0.998298,"marketCap":1159143771},{"date":"2020-10-05","current":-3.518245,"twenty":-3.193584,"median":-2.392077,"eighty":-0.998298,"marketCap":227127332}],"updateTime":1757305511609},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.aduro.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.0229},{"period":"3month","weight":0.0803},{"period":"6month","weight":0.1238},{"period":"1year","weight":0.1776},{"period":"ytd","weight":0.1044}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Aduro Biotech, Inc.最初是於2000年以Oncologic公司的名字在加利福尼亞州註冊成立。在2008年，該公司兼并了海衛生物系統公司，隨後於2009年更名為Aduro生物科技有限公司。2011年6月，該公司重新合併作為特拉華州的公司。該公司是臨床階段的免疫腫瘤公司專註於設計，以刺激對抗癌症堅固耐用的免疫反應第一的一流技術平台的發展，其先導候選產品是一項隨機對照2b期臨床試驗在轉移性胰腺癌。免疫腫瘤包括一種類療法，利用患者的免疫系統，以減慢的生長和擴散，或消除，腫瘤細胞。該公司目前的重點是開發和使用它的LADD和CDN技術平台的商業化最好的一流的癌症療法。","exchange":"NASDAQ","name":"Aduro Biotech, Inc.","nameEN":"Aduro Biotech"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ADRO\",market:\"US\",,,undefined,":null}}